Respiratory HealthMar 15, 2026
For years, a real concern hung over this drug: could adding a long-acting bronchodilator to an inhaled steroid increase the risk of serious asthma events? Large randomized controlled trials in adolescents and adults have now answered that clearly. Fluticasone salmeterol does not raise the risk of asthma-related deaths, intubations, or hospitalizations compared to fluticasone alone. What it does is reduce severe exacerbations by roughly 20 to 21%.
In COPD, the picture is more complicated. The symptom benefits hold up, but fluticasone salmeterol consistently increases pneumonia risk. Same drug, meaningfully different risk profiles depending on the disease being treated.
Sleep ApneaMar 15, 2026
For most people on positive airway pressure therapy, CPAP and BiPAP produce similar results on the outcomes that matter most: survival, avoiding intubation, and controlling sleep apnea. The research is consistent on this point across both acute hospital settings and long-term sleep disorder management. BiPAP isn't an upgrade from CPAP. It's a different tool, and the situations where it genuinely outperforms CPAP are more specific than many people realize.
The core difference is mechanical. CPAP (continuous positive airway pressure) pushes one steady pressure into your airway. BiPAP (bilevel positive airway pressure) delivers a higher pressure when you breathe in and a lower one when you breathe out. That second, lower pressure is what makes BiPAP feel easier to exhale against, and the higher inspiratory pressure can do extra work to help move air in and clear carbon dioxide.
COPDMar 13, 2026
The most widely used system for staging COPD does a solid job separating severe from very severe disease, but it struggles to distinguish early-stage COPD from normal lung function. A newer alternative flips this strength: it catches the early changes more reliably but loses some precision at the advanced end. Neither system alone tells the full story, and understanding what each one actually measures puts you in a much better position to interpret your own results.
COPD staging isn't just a label. It shapes which treatments doctors recommend, how aggressively they monitor you, and what your likely trajectory looks like. But the staging landscape is more complicated than a single number, and the system your pulmonologist uses determines what gets captured and what gets missed.
AsthmaMar 13, 2026
Fluticasone propionate is one of the most potent inhaled corticosteroids available, and less than 1% of each dose makes it past your lungs into the rest of your body. That's a feature, not a bug. It means strong local anti-inflammatory action with minimal systemic side effects. But that same intense local potency creates a split personality: in asthma, it's a highly effective controller. In COPD, it helps with symptoms but raises a real pneumonia risk that other inhaled steroids don't seem to carry to the same degree.
Understanding where fluticasone shines and where it gets complicated is the difference between using it well and using it blindly.
